The Effect of Sarpogrelate and High Dose Statin on the Reduction of Coronary Spasm

A Prospective, Single-center, Randomized Study to Evaluate the Effect of Sarpogrelate, a Selective Serotonin Receptor Antagonist, and High Dose Statin on the Reduction of Coronary Spasm in the Patients With Variant Angina

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01674686

Enrollment

200

Registered

2012-08-29

Start date

2012-08-01

Completion date

2018-12-31

Last updated

2018-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Variant Angina

Keywords

Vasospasm, Sarpogrelate, Statin

Brief summary

The aim of the study was to to evaluate the effect of sarpogrelate, a selective serotonin receptor antagonist, and high dose statin on the reduction of coronary spasm in the patients with variant angina.

Interventions

DRUGSarpogrelate

Sarpogrelate 100mg twice a day

DRUGAtorvastatin

Atorvastatin 80mg daily

Study design

Allocation

RANDOMIZED

Intervention model

FACTORIAL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

20 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Clinical history of chest pain compatible with variant angina; morning chest pain aggravated by cold exposure. * Angiographically proven coronary spasm; TIMI flow \< 3 by spontaneous coronary spasm or intracoronary ergonovine spasm provocation test.

Exclusion criteria

* Cardiac arrest by coronary spasm * Left main coronary spasm * Significant fixed coronary artery stenosis; Diameter stenosis \> 70% in the major epicardial artery by coronary angiography * Left ventricular ejection fraction \< 30% * Coagulation disorders or bleeding tendency (Platelet count \< 50k, PT INR \> 2.0) * Significant liver disease (AST or ALT \> 100 U/ml) * Renal failure (S-Cr \> 2.0 mg/dl) * hypersensitivity for statin * Pregnancy

Design outcomes

Primary

Measure	Time frame
Ergonovine provocation test 12months later	1 year later

Secondary

Measure	Time frame
C-reactive protein lever 12months later	1 year

Countries

South Korea

Contacts

Primary ContactHyeon-Cheol Gwon, MD,PhD

hcgwon@skku.edu82-2-3410-3419

Backup ContactJeong Hoon Yang, MD

jhysmc@gmail.com82-2-3410-3419

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026